(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2020 (17.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/251556 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61K 31/4418* (2006.01)
A61K 31/198 (2006.01)

(21) International Application Number:
PCT/US2019/036594

(22) International Filing Date:
11 June 2019 (11.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicants: **IO THERAPEUTICS, INC.** [US/US]; 5927 Almeda Road, Apt. #22105, Houston, Texas 77004 (US). **THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER** [US/US]; 1515 Holcombe Boulevard, Unit 1674, Houston, Texas 77030 (US).

(72) Inventors: **BROWN, M.D., PH.D., Powel H.**; Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Suite 8344, Houston, Texas 77030 (US). **SANDERS, Martin E.**; 1920 4th Avenue, #2704, Seattle, Washington 98191 (US).

(74) Agent: **CULLMAN, Louis C.** et al.; K&L Gates LLP, 1 Park Plaza, Twelfth Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*

(54) Title: USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS

(57) Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

Figure 1A





Figure 1B



WO 2020/251556 A1